No Data
Promising Potential of Corbus Pharmaceuticals: Buy Rating Reinforced by Key Assets and Strategic Focus
Express News | Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-in-Human Study of Crb-601 to Treat Patients With Advanced Solid Tumors
Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-In-Human Study of CRB-601 to Treat Patients With Advanced Solid Tumors
Corbus Pharmaceuticals Receives Fast Track From FDA for Cervical Cancer Treatment
Corbus Pharmaceuticals Announces U.S. FDA Granted FTD to CRB-701
Express News | Corbus Pharmaceuticals Holdings Inc - First Data From Dose Escalation Study Expected in Q1 2025
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}